Related Experiment Video

Updated: Jul 9, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

[Molecular mechanisms inhibiting proliferation of myeloma cells]

Yoshitaka Kikukawa1, Yutaka Okuno, Hiroyuki Hata

  • 1Department of Hematology, Kumamoto University Hospital.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|December 12, 2007
PubMed

Insights

This review summarizes molecules that inhibit myeloma cell proliferation, including cell cycle regulators and angiogenesis inhibitors. It also highlights the novel finding of growth inhibition by PU.1.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Multiple myeloma is characterized by uncontrolled proliferation of plasma cells.
  • Several endogenous molecules have been identified as inhibitors of myeloma cell growth and related processes.
  • Understanding these inhibitory mechanisms is crucial for developing novel therapeutic strategies.

Purpose of the Study:

  • To review the significance of known proliferation inhibitors in multiple myeloma.
  • To present novel findings on the growth inhibitory effects of PU.1 in myeloma cells.

Main Methods:

  • Literature review of molecules inhibiting myeloma cell proliferation.
  • Analysis of the role of PTEN, mTOR, p53, RB1, INK4, KIP/CIP, and PF4 in myeloma.
  • Explanation of experimental findings related to PU.1's effect on myeloma cell growth.

Main Results:

  • PTEN, mTOR, p53, RB1, INK4/KIP/CIP family proteins, and PF4 are key inhibitors of myeloma cell proliferation, cell cycle, and angiogenesis.
  • PU.1 demonstrates a significant growth inhibitory effect on myeloma cells.

Conclusions:

  • A variety of molecular pathways regulate myeloma cell proliferation and angiogenesis.
  • PU.1 represents a potential novel therapeutic target for inhibiting myeloma cell growth.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.